This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.
This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.
Testing Gene PilotLX With Latinx Cancer Patients
-
MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States, 08103
Herbert Irving Comprehensive Cancer Center, New York, New York, United States, 10032
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States, 19111
Temple University Hospital, Philadelphia, Pennsylvania, United States, 19122
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 80 Years
ALL
No
Fox Chase Cancer Center,
Michael J Hall, MD,MS, PRINCIPAL_INVESTIGATOR, Fox Chase Cancer Center
Sarah B Bass, PhD, MPH, PRINCIPAL_INVESTIGATOR, Temple University
Tracey A Revenson, PhD, PRINCIPAL_INVESTIGATOR, Hunter College of City University of New York
2027-12-31